/
Oncology
Head and Neck Tumors
4
Pipeline Programs↗
5
Active Trials↗
4
Companies Involved↗
Head and Neck Tumors is an early-stage landscape with 4 programs across 4 companies. The most active players are Grit Biotechnology.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 12
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
67%
Cell therapy
2 of 3 classified programs — the dominant modality here.
Cell therapy leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.
Analysis
Trial Status
10
clinical trials
Recruiting4 · 40%
Unknown status2 · 20%
Completed2 · 20%
Withdrawn1 · 10%
Not yet recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05758389·29 enrolled
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06240689·104 enrolled
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Completed·—·Phase 1·NCT00978081·35 enrolled
Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors
Unknown status·—·Phase 2·NCT05760196·56 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)